Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120159 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL120160 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL1802084 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL16661674 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL29416612 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL23979434 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL12846200 | 0.92 | KDM4E (0.32) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL12846267 | 0.92 | CA1 (0.31) | CA1CA2HTTRAB9A | |
| SCHEMBL12846253 | 0.92 | MAPT (0.33) | SMN1; SMN2CA1CA2HTTRAB9A | |
| SCHEMBL1799717 | 0.91 | SMN1; SMN2 (0.32) | SMN1; SMN2CA1CA2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3473101-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES | Intervet International B.V. (NL) | 2019-04-24 | — | — | EP | disclosed |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC (US) | 2015-04-23 | — | — | US | disclosed |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INTERNATIONAL B.V. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | PDK2 2373/4885SMN1; SMN2 4269/4885CA1 1771/4885 |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | PDK2 2373/4885SMN1; SMN2 4269/4885CA1 1771/4885 |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | PDK2 2373/4885SMN1; SMN2 4269/4885CA1 1771/4885 |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, EPX | PDK2 2347/4885SMN1; SMN2 4269/4885CA1 1649/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | PDK2 2373/4885SMN1; SMN2 4269/4885CA1 1771/4885 |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, AADAC | PDK2 2086/4885SMN1; SMN2 4300/4885CA1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.